Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atul Maini

Surgery Liverpool, NY Medical Doctor

NPI 1396700985 CMS profile 335629

5100 W Taft Rd Ste 2E, Upstate Surgical Group P.C., Liverpool, NY 13088

Open in the dashboard

General payments

$103,752

259 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Atul Maini of Liverpool, NY is reported in the CMS Open Payments database as having received $103,752 across 259 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,300 21
2024 General $2,636 61
2023 General $1,317 36
2022 General $25,626 65
2021 General $4,546 9
2020 General $7,620 13
2019 General $57,708 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atul Maini
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Atul Maini were reported at $4,300. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Atul Maini Surgery median Middle half National median
2019 $57,708 $253 $82–$1,521 $163
2020 $7,620 $131 $40–$706 $114
2021 $4,546 $168 $50–$904 $132
2022 $25,626 $224 $76–$1,218 $149
2023 $1,317 $253 $82–$1,255 $160
2024 $2,636 $279 $90–$1,381 $164
2025 $4,300 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $48,550 199 payments
  2. Ethicon US, LLC $41,436 25 payments
  3. Medical Device Business Services, Inc. $12,106 25 payments
  4. Ethicon Inc. $1,446 2 payments
  5. Covidien LP $85 1 payment
  6. Davol Inc. $47 2 payments
  7. Medtronic Vascular, Inc. $20 1 payment
  8. Medtronic, Inc. $19 1 payment
  9. AcelRx Pharmaceuticals, Inc. $15 1 payment
  10. TELA Bio, Inc. $15 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $49,216 15 payments
  2. Education $35,035 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,000 5 payments
  4. Travel and Lodging $5,569 18 payments
  5. Food and Beverage $5,325 200 payments
  6. Gift $608 3 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $48,550 199 payments
  2. LINX Reflux Management System Endo-Mechanical $44,518 29 payments
  3. LINX Reflux Management System Endo-Mechanical $566 7 payments
  4. EndoFlip $85 1 payment
  5. Phasix Mesh $47 2 payments
  6. Echelon Powered Circular $23 1 payment
  7. VenaSeal $20 1 payment
  8. PTEYE PARATHYROID DETECTION SYSTEM $19 1 payment
  9. DSUVIA $15 1 payment
  10. OviTex $15 1 payment
  11. Other $41 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

43

Median for General Surgery: 59

Drug cost

$217

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 32 $193
Neomycin Sulfate Generic 11 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$96,461

Medicare's payments for the services billed

Medicare patients

179

Average age 72

Services billed

364

95 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Diabetes 28%
Ischemic heart disease 27%
Chronic kidney disease 20%
Depression 20%
Cancer 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record